Compare ProShares Ultra QQQ ETF (QLD) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra QQQ ETF vs Summit Therapeutics Inc — how do they compare? ProShares Ultra QQQ ETF trades at $98.34 (market cap $15.38B), while Summit Therapeutics Inc trades at $17.45 (market cap $13.71B). The key difference: ProShares Ultra QQQ ETF and Summit Therapeutics Inc are close in size by market cap, and ProShares Ultra QQQ ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ProShares Ultra QQQ ETF for 36 Days and Summit Therapeutics Inc for 16 Days on average.
| QLD | SMMT | |
|---|---|---|
Market Cap | $15.38B | $13.71B |
Volume | 4,844,085 | 6,173,057 |
Sector | Leveraged / Inverse | Health |
52-Week High | $100.77 | $26.38 |
52-Week Low | $57.16 | $12.43 |
Typical Hold Time | 36 Days | 16 Days |
Enterprise Value | — | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QLD (ProShares Ultra QQQ ETF) trades at $98.12, down 2.11% on the day. Technical indicators show a bullish trend with moving averages supporting upside momentum while oscillators remain neutral. The ETF benefits from 2x leverage on the Nasdaq-100, providing amplified exposure to large-cap tech stocks. Recent institutional buying and media coverage highlight continued investor interest in leveraged tech exposure.
Outlook remains cautiously optimistic given the bullish technical setup and institutional accumulation, though leveraged ETFs carry elevated volatility risks during market downturns. The key opportunity lies in continued tech sector strength, while the primary risk involves amplified losses if the Nasdaq-100 declines significantly.
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
